AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8885732
Drug: Magnesium chloride
RxNorm normalized name: Magnesium Chloride
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium chloride 128 mg orally every 4 hours
Trial: 8402734
Drug: 0.18 MIU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.18 MIU/m2 IL-2 s.c. once weekly
Trial: 8402734
Drug: 0.9 MIU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 MIU/m2 IL-2 s.c. thrice weekly every other day
Trial: 8402734
Drug: 4.5 MIU/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 MIU/m2 IL-2 s.c. five times weekly every other week
Trial: 3710959
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g aztreonam iv twice daily for 4 to 15 days
Trial: 3710959
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefotaxime iv twice daily for 4 to 15 days
Trial: 29413437
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for NAS
Trial: 18767580
Drug: Scalp acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp acupuncture combined with rehabilitation therapy (group C)
Trial: 18767580
Drug: Rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation therapy (group B)
Trial: 16507374
Drug: Calcium +
RxNorm normalized name: Calcium + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium + Vitamin D (calcium carbonate 500 mg and vitamin D3 400 IU taken twice daily)
Trial: 12358234
Drug: Lansoprazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (15 mg or 30 mg once daily)
Trial: 3915459
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg b.i.d.)
Trial: 1860433
Drug: Endotracheal suction
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotracheal suction 6-hourly
Trial: 1860433
Drug: Endotracheal suction
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endotracheal suction 12-hourly
Trial: 6434794
Drug: Glibenclamide 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide 10 mg/d for 6 weeks
Trial: 29907752
Drug: microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microcrystalline cellulose pellets (500 mg samples)
Trial: 20093909
Drug: Daily gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily gentamicin (5 mg/kg IV, then 2 placebo doses IV after 8 and 16 hours)
Trial: 20093909
Drug: 8-hour gentamicin
RxNorm normalized name: gentamicin 0.8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-hour gentamicin (2 mg/kg IV, then 1.5 mg/kg IV after 8 and 16 hours)
Trial: 20093909
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received ampicillin (2 grams IV every 6 hours for a total of four doses) and patients who underwent cesarean delivery also received clindamycin (900 mg IV every 8 hours, for a total of three doses).
Trial: 10207779
Drug: OAC 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC 20 regimen (Omeprazole 20 mg daily, Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Trial: 10207779
Drug: LAC 30
RxNorm normalized name: etodolac 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAC 30 regimen (Lansoprazole 30 mg daily, Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Trial: 10207779
Drug: OAC 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC 40 regimen (Omeprazole 20 b.d., Amoxycillin 500 mg t.d.s., Clarithromycin 200 mg b.d.)
Trial: 334315
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage haloperidol (100 mg daily) for three months
Trial: 334315
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage haloperidol (100 mg daily)
Trial: 31385001
Drug: Quizartinib 30
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib 30 mg alone (reference)
Trial: 31385001
Drug: Lansoprazole 60
RxNorm normalized name: dexlansoprazole 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 60 mg once daily (days 1-5) + single-dose quizartinib 30 mg (day 5) (test)
Trial: 26337978
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 100 μg/vilanterol 25 μg once-daily
Trial: 26337978
Drug: Existing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing therapy (control group)
Trial: 23578227
Drug: N7‐GP 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N7‐GP 25 μg kg(‐1)
Trial: 23578227
Drug: N7‐GP 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N7‐GP 100 μg kg(‐1)
Trial: 23578227
Drug: N7‐GP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N7‐GP 200 μg kg(‐1)
Trial: 23578227
Drug: N7‐GP (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N7‐GP (all doses)
Trial: 23578227
Drug: Observation period
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation period with on-demand treatment of rFVIIa
Trial: 19188550
Drug: Bosentan (62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosentan (62.5 mg on day 1, 125 mg on days 2 and 3)
Trial: 17307892
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (1500 impulses at 14 KV)
Trial: 17307892
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (nonsteroidal anti-inflammatory drugs, physiotherapy, exercise program, knee strap)
Trial: 14996107
Drug: 0.1% melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% melatonin applied once daily for 6 months
Trial: 14996107
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution applied once daily for 6 months
Trial: 11697758
Drug: Dofetilide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide (0.5 mg bid)
Trial: 11697758
Drug: Dofetilide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide (0.5 mg bid) + Verapamil (80 mg tid)
Trial: 10365287
Drug: Inogatran (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inogatran (low dose)
Trial: 10365287
Drug: Inogatran (medium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inogatran (medium dose)
Trial: 10365287
Drug: Inogatran (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inogatran (high dose)
Trial: 3370405
Drug: Salad with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salad with toppings (600 g) with small beverage
Trial: 3370405
Drug: Carbonated beverage
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbonated beverage (800 ml)
Trial: 3370405
Drug: Bean burritos
RxNorm normalized name: Bean
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bean burritos and one bean tostada (900 g) with small beverage
Trial: 29666118
Drug: Initial R-chemotherapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial R-chemotherapy ± R maintenance
Trial: 26254752
Drug: Landiolol hydrochloride
RxNorm normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Landiolol hydrochloride (ultrashort‐acting β‐blocker)
Trial: 23823157
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus cisplatin with twice-daily radiation
Trial: 23823157
Drug: Fluorouracil plus
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil plus cisplatin with twice-daily radiation
Trial: 18552270
Drug: Erythropoietin stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin stimulating agents (ESAs)
Trial: 16616165
Drug: 21 mg
RxNorm normalized name: aspirin 421 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 mg nicotine patch (NP)
Trial: 16616165
Drug: 42 mg
RxNorm normalized name: lithium 42 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 42 mg nicotine patch (NP)
Trial: 15030300
Drug: Therapies targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapies targeted against reactive oxygen intermediates (not specified dosage or duration)
Trial: 15030300
Drug: Antioxidants (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (not specified dosage or duration)
Trial: 8618139
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (2000 or 3000 mg for 16 weeks)
Trial: 6741150
Drug: 2 times
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 times 250 ml protein‐free dialysate of calf blood (Solcoseryl) in saline solution over 9 days
Trial: 31619359
Drug: Topical natamycin
RxNorm normalized name: Natamycin
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical natamycin 5% plus CXL
Trial: 31619359
Drug: Topical natamycin
RxNorm normalized name: Natamycin
DrugBank: Natamycin (DB00826)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical natamycin 5% alone
Trial: 31619359
Drug: Topical amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical amphotericin B 0.15% alone
Trial: 24120672
Drug: Intradermal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccine (15μg HA/strain)
Trial: 24120672
Drug: Intradermal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccine (21μg HA/strain)
Trial: 24120672
Drug: High-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intramuscular vaccine (60μg HA/strain)
Trial: 24120672
Drug: Standard-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose intramuscular vaccine (15μg HA/strain)
Trial: 22674470
Drug: Oral solution
RxNorm normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral solution of 10 μg deuterated Phenanthrene ([D₁₀]Phe)
Trial: 22674470
Drug: Smoking cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking cigarettes containing 10 μg deuterated Phenanthrene ([D₁₀]Phe)
Trial: 12232564
Drug: Verapamil (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0.15 mg/kg at a rate of 2 mg/min)
Trial: 12232564
Drug: Ibutilide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (1 mg over 10 minutes)
Trial: 10086657
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (400 mg twice daily) plus metronidazole (400 mg) and tetracycline (500 mg) four times daily for 1 week (RMT)
Trial: 10086657
Drug: Colloidal bismuth
RxNorm normalized name: Colloidal bismuth subcitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloidal bismuth subcitrate (120 mg), metronidazole (400 mg), and tetracycline (500 mg) four times daily for 1 week (BMT)
Trial: 7394499
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg oxitropium bromide
Trial: 7394499
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg oxitropium bromide at 7.30 a.m. after placebo
Trial: 19438539
Drug: M. vaccae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M. vaccae (intradermal injection, three times at 2-week intervals)
Trial: 19438539
Drug: Placebo (intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intradermal injection, three times at 2-week intervals)
Trial: 15145972
Drug: Omeprazole (OM)
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole (OM) 20 mg bid with bismuth biskalcitrate, metronidazole, and tetracycline
Trial: 8076440
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 1 alpha‐OHD3 (80 ng/kg BW)
Trial: 8076440
Drug: Intraperitoneal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal administration of 1 alpha‐OHD3 (80 ng/kg BW)
Trial: 8076440
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 1 alpha‐OHD3 (80 ng/kg BW)
Trial: 2760214
Drug: Estrogen therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen therapy for 3 months
Trial: 2760214
Drug: Chronic estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic estrogen therapy
Trial: 30566177
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR-NTX) 380 mg every 4 weeks
Trial: 30566177
Drug: Buprenorphine-naloxone (BP-NLX)
RxNorm normalized name: buprenorphine / naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine-naloxone (BP-NLX) flexible doses (4-24 mg; target dosage 16 mg/d)
Trial: 23625291
Drug: Plecanatide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plecanatide (0.1 to 48.6 mg)
Trial: 20971975
Drug: Rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (8 mg once daily for 8 weeks)
Trial: 16769932
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS and placebo medication
Trial: 12776447
Drug: Budesonide Turbuhaler
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide Turbuhaler (400 micrograms) once daily
Trial: 10669275
Drug: Propacetamol 60
RxNorm normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 60 mg kg(‐1) i.v.
Trial: 10669275
Drug: Ketorolac 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 0.4 mg kg(‐1) i.v.
Trial: 9062568
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy combined with incentive spirometry (IS)
Trial: 9062568
Drug: Postoperative pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative pulmonary physical therapy (breathing exercises, secretion removal, mobility)
Trial: 8406337
Drug: Human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human growth hormone (HGH) 4 IU/m2/day for 2 years
Trial: 8406337
Drug: Human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human growth hormone (HGH) 3 IU/m2/day for 2 years
Trial: 8406337
Drug: Human growth
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human growth hormone (HGH) 2 IU/m2/day for 2 years
Trial: 29579957
Drug: Treatment 1
RxNorm normalized name: CVS Acne Treatment 10% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 1 - received general information and information about the benefits (positive attributes)
Trial: 29579957
Drug: Treatment 2
RxNorm normalized name: epoch Blemish Treatment 2 % Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment 2 - received general information and information about the potential drawbacks (negative attributes)
Trial: 12065968
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution of powdered sweetener (Zero Cal)
Trial: 12065968
Drug: 1.5% lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% lactose solution
Trial: 12065968
Drug: 1.5% sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% sucrose solution
Trial: 9726444
Drug: rG‐CSF 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rG‐CSF 5 microg/kg for 5 consecutive days starting 7 days before chemotherapy with etoposide and cisplatin.
Trial: 9726444
Drug: Course 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Course 2 results after chemotherapy.
Trial: 30689759
Drug: Azithromycin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (1 g single dose)
Trial: 7974076
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg 4 times daily for 7 days)
Trial: 2566827
Drug: haem arginate
RxNorm normalized name: Haem arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: haem arginate 3 mg/kg per 24 h for 4 days
Trial: 31948466
Drug: EPA +
RxNorm normalized name: Eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPA + DHA (1.87 g/day of EPA + 1.0 g/day of DHA)
Trial: 8099789
Drug: Cognitive Treatment
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Treatment (CT)
Trial: 31127076
Drug: Physical Treatment
RxNorm normalized name: SUNSCREEN 30-50/PHYSICAL BLOCK/PABA-FREE, COMBO LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Treatment (PT)
Trial: 26323938
Drug: Control (guideline-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (guideline-based medical treatment alone)
Trial: 9438480
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg BD for 8 weeks
Trial: 9438480
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg OD for 8 weeks
Trial: 9438480
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg OD for 4 weeks followed by FPANS 200 microg BD for 4 weeks
Trial: 9438480
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily for 8 weeks
Trial: 8497284
Drug: Aerosolized tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aerosolized tobramycin (600 mg for 28 days)
Trial: 30891999
Drug: Bi-level positive
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bi-level positive airway pressure ventilation in addition to conventional treatment
Trial: 30891999
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment including continuous oxygen inhalation, anti-infection, bronchodilation, phlegm resolving, nutrition support, analgesia, cardiac function maintenance, coronary dilatation, anticoagulation
Trial: 21224868
Drug: Daily dose
RxNorm normalized name: LENVIMA 8mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 7.5 μg of vitamin D₃ for 12 months, increasing to 22.5 μg for the remaining 18 months through fortified dairy products and nutrition and lifestyle counselling sessions
Trial: 19042080
Drug: ZD4054 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD4054 10 mg
Trial: 19042080
Drug: ZD4054 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZD4054 15 mg
Trial: 16453185
Drug: Nipradilol 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipradilol 0.25% twice daily for 3 months
Trial: 16453185
Drug: Carteolol 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol 2% twice daily for 3 months
Trial: 15246467
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (APDs) + Antidepressants
Trial: 15246467
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (APDs)
Trial: 11726261
Drug: L-carnitine L-tartrate
RxNorm normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine L-tartrate (LCLT) 3 g/day for 3 weeks
Trial: 9230328
Drug: Acetaminophen with
RxNorm normalized name: acetaminophen with codeine ORAL ELIXIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen with codeine (group 1)
Trial: 9230328
Drug: Ibuprofen (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (group 2)
Trial: 8390548
Drug: Trivalent vaccine
RxNorm normalized name: Fluzone 2024-2025 trivalent vaccine Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent vaccine containing 10(4) TCID50 of B
Trial: 8390548
Drug: Monovalent B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent B vaccine of the same dose (10(4) TCID50)